                         SEQUENCE LISTING

<110>  The University of Hull
 
<120>  Therapeutic Use

<130>  P031106WO

<150>  GB1700526.5
<151>  2017-01-12

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  380
<212>  PRT
<213>  Homo Sapiens

<400>  1

Met Ser Glu Thr Val Ile Cys Ser Ser Arg Ala Thr Val Met Leu Tyr 
1               5                   10                  15      


Asp Asp Gly Asn Lys Arg Trp Leu Pro Ala Gly Thr Gly Pro Gln Ala 
            20                  25                  30          


Phe Ser Arg Val Gln Ile Tyr His Asn Pro Thr Ala Asn Ser Phe Arg 
        35                  40                  45              


Val Val Gly Arg Lys Met Gln Pro Asp Gln Gln Val Val Ile Asn Cys 
    50                  55                  60                  


Ala Ile Val Arg Gly Val Lys Tyr Asn Gln Ala Thr Pro Asn Phe His 
65                  70                  75                  80  


Gln Trp Arg Asp Ala Arg Gln Val Trp Gly Leu Asn Phe Gly Ser Lys 
                85                  90                  95      


Glu Asp Ala Ala Gln Phe Ala Ala Gly Met Ala Ser Ala Leu Glu Ala 
            100                 105                 110         


Leu Glu Gly Gly Gly Pro Pro Pro Pro Pro Ala Leu Pro Thr Trp Ser 
        115                 120                 125             


Val Pro Asn Gly Pro Ser Pro Glu Glu Val Glu Gln Gln Lys Arg Gln 
    130                 135                 140                 


Gln Pro Gly Pro Ser Glu His Ile Glu Arg Arg Val Ser Asn Ala Gly 
145                 150                 155                 160 


Gly Pro Pro Ala Pro Pro Ala Gly Gly Pro Pro Pro Pro Pro Gly Pro 
                165                 170                 175     


Pro Pro Pro Pro Gly Pro Pro Pro Pro Pro Gly Leu Pro Pro Ser Gly 
            180                 185                 190         


Val Pro Ala Ala Ala His Gly Ala Gly Gly Gly Pro Pro Pro Ala Pro 
        195                 200                 205             


Pro Leu Pro Ala Ala Gln Gly Pro Gly Gly Gly Gly Ala Gly Ala Pro 
    210                 215                 220                 


Gly Leu Ala Ala Ala Ile Ala Gly Ala Lys Leu Arg Lys Val Ser Lys 
225                 230                 235                 240 


Gln Glu Glu Ala Ser Gly Gly Pro Thr Ala Pro Lys Ala Glu Ser Gly 
                245                 250                 255     


Arg Ser Gly Gly Gly Gly Leu Met Glu Glu Met Asn Ala Met Leu Ala 
            260                 265                 270         


Arg Arg Arg Lys Ala Thr Gln Val Gly Glu Lys Thr Pro Lys Asp Glu 
        275                 280                 285             


Ser Ala Asn Gln Glu Glu Pro Glu Ala Arg Val Pro Ala Gln Ser Glu 
    290                 295                 300                 


Ser Val Arg Arg Pro Trp Glu Lys Asn Ser Thr Thr Leu Pro Arg Met 
305                 310                 315                 320 


Lys Ser Ser Ser Ser Val Thr Thr Ser Glu Thr Gln Pro Cys Thr Pro 
                325                 330                 335     


Ser Ser Ser Asp Tyr Ser Asp Leu Gln Arg Val Lys Gln Glu Leu Leu 
            340                 345                 350         


Glu Glu Val Lys Lys Glu Leu Gln Lys Val Lys Glu Glu Ile Ile Glu 
        355                 360                 365             


Ala Phe Val Gln Glu Leu Arg Lys Arg Gly Ser Pro 
    370                 375                 380 


<210>  2
<211>  20
<212>  PRT
<213>  Artificial

<220>
<223>  N-terminal VASP peptide


<220>
<221>  X
<222>  (9)..(9)
<223>  methylated arginine residue

<400>  2

Ser Glu Thr Val Ile Cys Ser Ser Xaa Ala Thr Val Met Leu Tyr Asp 
1               5                   10                  15      


Asp Gly Asn Lys 
            20  


